Revisiting the medication possession ratio threshold for adherence in lipid management

Current Medical Research and Opinion

Volumn 29, Issue 3, 2013, Pages 175-180

  Watanabe, Jonathan H ^a   Bounthavong, Mark ^b   Chen, Timothy ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Lipids; Medication Possession Ratio; Outcomes

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MEDICATION POSSESSION RATIO; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

CHOLESTEROL; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873639341     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.766164     Document Type: Article

References (24)

1. Osterberg L, Blaschke T. Adherence to medication. N. Engl J Med 2005;353:487-97
2. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-30
3. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; (2):CD000011
4. Kripalani S. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540-549
5. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
6. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States. A systematic review. Ann Intern Med 2012; doi: 10.7326/0003-4819-157-11- 201212040-00538. [Epub ahead of print]
7. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010;362:1553-5
8. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Affairs 2007;26:97-110
9. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
10. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
11. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48
12. Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012;50:870-5
13. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
14. Zhang Y, Lave JR, Donohue JM. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care 2010;48:409-17
15. Yang M, Barner JC, Worchel J. Factors related to antipsychotic oversupply among Central Texas Veterans. Clin Ther 2007;29:1214-25
16. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46:1-7
17. Oleen-Burkey MA, Dor A, Castelli-Haley J, et al. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ 2011;14:739-47
18. Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
19. Grundy SM. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
20. Gotto AM, Grundy SM. Lowering LDL cholesterol: questions from recent metaanalyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting. Circulation 1999;99:e1-7
21. Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J American Coll Cardiol 2009;53:316-22
22. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-19
23. Kastelein JJP, Van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9
24. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff 2012;31:2276-85